Reason for request
Inclusion on the list of medicines reimbursed by National Insurance (B/5 and B/20) and approved for use by hospitals (B/5, B/20 and B/30).
Clinical Benefit
Low |
the actual benefit of VERSATIS 5% lidocaine plasters in the treatment of PHN is low in view of its weak efficacy demonstrated versus placebo.
|
Clinical Added Value
no clinical added value |
VERSATIS offers no improvement in actual benefit compared to the current treatment strategy (IAB V).
|
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
wvTXHcSEVrqJCX3a